Pegylated liposomal doxorubicin (Doxil®) is active in the treatment of relapsed/refractory lymphomas.

被引：0
|
作者：
Tulpule, A
Justice, G
Espina, BM
Harvey-Buchanan, L
Barut, L
Khan, A
Levine, AM
机构：
[1] USC, Sch Med, Los Angeles, CA USA
[2] Fountain Valley Reg Canc Ctr, Fountain Valley, CA USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4035
引用
收藏
页码：241B / 241B
页数：1
相关论文
共 50 条
  • [1] Study of pegylated liposomal doxorubicin in first line therapy of aggressive lymphomas.
    Mandala, E
    Lafaras, C
    Ilonidis, G
    Venizelos, I
    Grollios, G
    Tsioni, C
    Bischiniotis, T
    Arvanitakis, C
    [J]. BLOOD, 2005, 106 (11) : 261B - 261B
  • [2] DOXIL (pegylated liposomal doxorubicin): Clinical, update
    Martin, FJ
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 34 - CARB
  • [3] Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.
    Abruzzese, Elisabetta
    Postorino, Massimiliano
    Faraggiana, Tullio
    Renzi, Daniela
    Rizzo, Manuela
    Quaresima, Micol
    Pupo, Livio
    Cannarsa, Roberta
    Spagnoli, Alessandra
    Vaccarini, Sara
    Trawinska, Malgorzata Monika
    Anemona, Lucia
    Lombardo, Giuseppe
    Cantonetti, Maria
    [J]. BLOOD, 2009, 114 (22) : 1432 - 1432
  • [4] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [5] Pegylated Liposomal Doxorubicin A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
    Plosker, Greg L.
    [J]. DRUGS, 2008, 68 (17) : 2535 - 2551
  • [6] Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas
    Braunstein, Zachary
    Waller, Allyson
    Dotson, Emily
    McLaughlin, Eric
    Hanel, Walter
    Reneau, John
    Addison, Daniel
    Porcu, Pierluigi
    Brammer, Jonathan Edward
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 301 - 311
  • [7] Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas
    Braunstein, Zachary
    Waller, Allyson
    Dotson, Emily
    McLaughlin, Eric
    Hanel, Walter
    Reneau, John C.
    Addison, Daniel
    Porcu, Pierluigi
    Brammer, Jonathan E.
    [J]. BLOOD, 2023, 142
  • [8] A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
    Jonas, Brian A.
    Potter, Laura A.
    Galkin, Maria
    Tuscano, Joseph M.
    [J]. LEUKEMIA RESEARCH REPORTS, 2023, 19
  • [9] The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (DOXIL®)
    Szebeni, J
    Baranyi, L
    Savay, S
    Lutz, HU
    Jelezarova, E
    Bunger, R
    Alving, CR
    [J]. JOURNAL OF LIPOSOME RESEARCH, 2000, 10 (04) : 467 - 481
  • [10] Pegylated Liposomal Doxorubicin (PLD) in the treatment of advanced Cutaneous Lymphomas
    Cantonetti, M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : S14 - S14
12345